2Yawn BP, GildenD. The global epidemiology of herpes zoster[J]. Neurology, 2013,3,81 : 928-930.
3Pinchinat S, Cebridn-Cuenca AM, Bricout H, et al. Similar herpes zoster incidence across Europe: results from a systematic literature review[J]. BMC Infect Dis, 2013, 13:170.
4Nagel MA, Gilden D. Complications of varicella zoster virus reactivation [J]. Curr Treat Options Neurol, 2013,15:439-453.
5Srinivas N,Matthew W, Leah B, et al. Influence of anatomic location of lidocaine patch 5% on effectiveness and tolerability for postherpetie neuralgia[J]. Adherence, 2013, 7: 551-557.
6Kanbayashi Y, Hosokawa T. Vaccination against and treatment of acute herpes zoster for prevention of post herpetic neuralgia[J]. Curr Pain Headache Rep, 2013,17:371.
7Doan HQ, Ung B, Ramirez-Fort MK, et al. Zostavax : a subcutaneous vaccine for the prevention of herpes zoster[J]. Expert Opin Biol Ther, 2013, 13:1467-1477.
8Keating GM. Shingles ( herpes zoster ) vaccine (zostavax) : a review of its use in the prevention of herpes zoster and postherpetie neuralgia in adults aged≥50 years[J]. Drugs, 2013, 73:1227-1244.
9Reda H, Greene K, Rice FL, et al. Natural history of herpes zoster: late follow-up of 3.9 years (n=43) and 7.7 years (n=10)[J]. Pain, 2013,154:2227-2233.
